StockData
Aethlon Medical Inc logo

Aethlon Medical Inc (AEMD) stock

AEMDNasdaqPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$5.11+0.03 (+0.59%)

Close on Nov 18, 2026Market cap $3.63MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$3.63M
P/E ratio
–
Price to sales
–
Price to book
0.70
Dividend yield
–
Free cash flow yield
-192.69%

Fundamentals

Net income
-$7.15M
EPS, diluted
-$10.61
Free cash flow
-$7.00M
Book value per share
$13.52
Diluted shares
0M

Trading

Next earnings
Feb 11, 2027 (estimated, after the close)
Previous close
$5.08
Open
$5.13
Day's range
$4.98 – $5.15
Volume
11,574
Average volume (20 days)
41,900
Beta (5 years)
1.32
52-week range
$1.41 – $24.75
RSI (14 days)
45.2
Volatility (1 year)
387.8%
Relative volume
0.01×
WACC
11.7%

Market cap history

Month-end market cap since 2011, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.

PeriodAEMDS&P 500DifferenceAEMD per yearS&P 500 per year
1 month-0.8%-4.3%+3.6 pts
3 months+76.8%-4.6%+81.4 pts
Year to date-63.1%+7.9%−71.0 pts
1 year-75.7%+11.8%−87.5 pts
3 years-99.2%+68.0%−167.2 pts-80.1%+18.9%
5 years-100.0%+66.2%−166.2 pts-78.4%+10.7%
10 years-100.0%+291.3%−391.3 pts-66.4%+14.6%

Fifteen years at a glance

Fiscal years 2012 to 2026, USD

Revenue

–

Operating income

-$7.29M

Net income

-$7.15M

EPS, diluted

-$10.61

Free cash flow

-$7.00M
Reported period

Press releases

Releases Aethlon Medical filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Aethlon Medical

Pharmaceutical Preparations

Aethlon Medical, Inc. is a medical therapeutic company engaged in developing the Hemopurifier, a clinical-stage investigational immunotherapeutic device. The device uses lectin-based technology to bind and clear enveloped viruses and extracellular vesicles from biological fluids, targeting unmet clinical needs in oncology, life-threatening viral infections, and organ transplantation. Within oncology, the company focuses on removing disease-associated extracellular vesicles to counteract immune suppression and tumor metastasis in patients with advanced or metastatic solid tumors undergoing anti-PD-1 monotherapy.

Company profile, executives and history

Aethlon Medical stock: common questions

What is Aethlon Medical's stock price?

AEMD closed at $5.11 on Nov 18, 2026, up 0.59% on the day. Over the past 52 weeks it traded between $1.41 and $24.75.

What is Aethlon Medical's market cap?

Aethlon Medical was worth $3.63M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.

What is AEMD's P/E ratio?

Aethlon Medical lost money over the twelve months to Mar 31, 2026 (diluted EPS -$10.61), so it has no meaningful P/E ratio.

Does Aethlon Medical pay a dividend?

No. Aethlon Medical has not paid a cash dividend over the last twelve months.

When does Aethlon Medical report earnings next?

Aethlon Medical is expected to report Q3 FY2027 results on Feb 11, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has AEMD stock performed over the past year?

Including dividends, AEMD returned -75.7% over the past year, against +11.8% for the S&P 500.

How many AEMD shares are sold short?

0M shares were sold short at the latest FINRA report, 7.08% of the float, or 1.0 days of average trading volume.

Who are Aethlon Medical's competitors?

Companies most similar to Aethlon Medical by business, industry and size include ELDN, IMMX, ANAB, LYEL, BIXT.

See a number that looks wrong?